Download ILSI Health and Environmental Sciences Institute

HESI
ILSI Health and Environmental Sciences Institute
HESI PROTEIN ALLERGENICITY TECHNICAL COMMITTEE
Bioinformatics Expert Panel Workshop
February 22 – 24, 2005 Mallorca, Spain
Monograph Outline
Chapter
1.
Chapter Scope
Food allergy review
A. Prevalence
B. Clinical manifestations
C. Risks from conventional food supply
Primary Author(s)
Wesley Burks (Duke
University Medical Center)
2.
Review of the development of methodology for evaluating the human
allergenic potential of novel proteins (Steve Taylor (Nebraska), Sue Hefle
(Nebraska)
Steve Taylor
*†
(Nebraska)
A. Presentation of general approach for a typical bioinformatics
comparison
B. Risks from foods containing proteins introduced through biotechnology
3.
Introduction to Bioinformatics
Pinar Kondu*†
IONTEK, INC., Istanbul,
Turkey
4.
Is there a minimum size constraint and number of sites for a protein to
effectively cross-link IgE on mast cell/basophil receptors and induce
mediator release? (Relevant for pepsin digestion as well as
sequence/structural evaluations.)
Edward F. Knol*†
(University Medical Center
Utrecht)
5.
Evaluation of structural biology in the context of cross-reactivity
Rob Aalberse*†
Items to be addressed:
Rob Aalberse and a second individual (Part 1)
Heimo Breiteneder†
(Austria)
Clare Mills†
1.
Minimum shared sequence identities indicating likely crossreactivity
a.
i.
ii.
iii.
Serum IgE binding data
Specificity
Relative abundance
Cross-reactivity determined by inhibition, not just direct binding
1
HESI
ILSI Health and Environmental Sciences Institute
Chapter
Chapter Scope
b.
Evaluation of data relative to the FAO/WHO 2001
recommendation of 35% identity over >80 contiguous amino acids
c.
Evaluate food allergens and aeroallergens
Primary Author(s)
2.
Is either a short-segment amino acid matching programs or a
structural comparison program better at predicting cross-reactivity than
FASTA or BLASTP?
Heimo Breiteneder and Clare Mills (Part 2)
1.
Is there an example of allergic cross reactivity between nonhomologous proteins?
a.
b.
Proteins sharing significant IgE cross-reactivity?
If so, evidence of clinical significance?
2.
Can cross-reactive conformational epitopes be predicted?
a.
By FASTA or BLASTP?
b.
By structural prediction algorithms?
c.
Is prediction restricted to highly homologous proteins or
families?
6.
7.
Review of available allergen databases.
What were the criteria used to develop these particular databases?
(historical discussion)
Allergen database definitions
Steve Gendel*† (US FDA
NCFST)
Evaluation of available IgE binding data and its utility in bioinformatics
Gary Bannon*†
(Monsanto)
John Jenkins† – (Institute of
Food Research UK)
Tadashi Ogawa † (Kyoto
University, Japan)
8.
Utility and methods of allergen specific IgE testing in the diagnosis of
food allergy (including binding and inhibition tests)
Ronald van Ree*†
Stefan Vieths
9.
Serum IgE testing in the event of a positive match in the bioinformatics
searches (Company, Pharmacia Diagnostics, Andrew Saxon-CA, Hugh
Sampson-NY)
2
Lars Poulsen*†
(Denmark)
HESI
ILSI Health and Environmental Sciences Institute
Chapter
10.
Chapter Scope
Development of Executive Summary and Overall Recommendations
Primary Author(s)
Editorial Board:
Rob Aalberse†
Jim Astwood†
Wesley Burks
Sue Hefle†
Greg Ladics†
Sue MacIntosh†
Hugh Sampson
Steve Taylor†
*
Lead Author
†Participation Confirmed
3